Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Valrubicin.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Valrubicin.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Valrubicin.
Advertisement
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Valrubicin.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Valrubicin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Valrubicin.
Advertisement
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Valrubicin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Valrubicin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Valrubicin.
Advertisement
Digoxin
Digoxin may decrease the cardiotoxic activities of Valrubicin.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Valrubicin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Valrubicin.
Ouabain
Ouabain may decrease the cardiotoxic activities of Valrubicin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Valrubicin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Valrubicin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Valrubicin.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Valrubicin.
